Allos Therapeutics (ALTH) Reports Inline Q3 Loss of $0.21
ALTH Hot Sheet
EPS Growth %: +16.7%Financial Fact:
License and other revenue: 1.58M
Today's EPS Names:
TARO, BRLI, TLB, More
Allos Therapeutics, Inc. (NASDAQ: ALTH) reports Q3 loss of $0.21, inline with the analyst estimate of ($0.21).
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- Tsakos Energy Navigation Ltd. (TNP) Posts Narrower than Expected Q1 Loss
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
